|[January 10, 2013]
Pall Corporation Magnifies Focus on Instrumentation with Expansion of Menlo Park Facility
PORT WASHINGTON, N.Y. --(Business Wire)--
Pall Corporation (NYSE:PLL),
a global leader in filtration, separation and purification, today
announced that it has expanded its Menlo Park, California facility, the
site of its ForteBio®
operations, to create a Center of Excellence (COE) for Instrumentation.
The expanded COE, located in the heart of the Silicon Valley/Bay area,
occupies more than 42,000 sq. feet on two floors, which is nearly double
the size of the original facility. The multi-disciplinary center handles
a broad range of functions from instrument and consumable reagent
manufacturing to product development. Acquired by Pall in 2012, ForteBio
is a division of Pall
"Process instrumentation represents an important growth market for
Pall," said Yves Baratelli, president, Pall Life Sciences. "By creating
a center that focuses on instrumentation and process monitoring system
design and development, we are now better positioned to meet the
evolving needs of our research and drug development customers worldwide.
The location of the new COE also will allow us to capitalize on emerging
opportunities in strategic local areas such as the Silicon Valley
To further demonstrate Pall's commitment to meeting the widening range
of analytical, testing and monitoring needs of its customers, Pall
doubled its Menlo Park facility's engineering staff and now operates its
Global Instrumentation Field Service Group from the site. Having the
field service, design engineeringand manufacturing teams housed at the
same facility will enable Pall to build greater serviceability into its
solutions. The facility also offers customer training.
ForteBio's flagship Octet®
instrumentation platform and related consumable reagents, as well as the
revolutionary smaller scale BLItz™
system, continue to be manufactured at the Menlo Park facility. The
BLItz system enables scientists to easily and cost-effectively conduct
label-free analyses of proteins using small sample volumes right at
their lab bench.
Additional activities being performed at the site include manufacturing
of the Pall®
Micro-24 MicroReactor process development system for cell culture
and leading-edge software development related to Pall's GeneDisc®
pathogen detection platform.
While the current focus of the COE is on life sciences applications,
Pall plans to make the COE an authority on all Pall instrumentation
design and development opportunities.
About Pall Life Sciences
Pall Life Sciences provides cutting-edge products and services to meet
the demanding needs of customers discovering, developing and producing
biotech drugs, vaccines and classic pharmaceuticals. Pall's membranes
and membrane devices optimize detection and sample preparation in the
drug research, clinical diagnostics, genomics, and proteomics markets.
Pall is a leading provider of separation systems and single-use
filtration and purification technologies to pharmaceutical and
biotechnology companies to support faster development of new drugs and
vaccines that are safer and require less energy and water to produce.
Pall technologies are also used in clinical institutions and the food
and beverage industries.
About Pall Corporation
Pall Corporation (NYSE:PLL)
is a filtration, separation and purification leader providing solutions
to meet the critical fluid management needs of customers across the
broad spectrum of life sciences and industry. Pall works with customers
to advance health, safety and environmentally responsible technologies.
The company's engineered products enable process and product innovation
and minimize emissions and waste. Pall Corporation is an S&P 500 company
serving customers worldwide. Pall has been named a "top green company"
by Newsweek magazine. To see how Pall is helping enable a
greener, safer, more sustainable future, follow us on Twitter (News - Alert) @PallCorporation
or visit www.pall.com/green.
[ Back To TMCnet.com's Homepage ]